USA: +1 617 939 9497 | UK: +44 2039 962936 | EU: +34 607 939 266 info@sofpromed.com
Select Page

CRO for Real-World Evidence (RWE) Studies

Patricio Ledesma

Sofpromed's CEO and Founder. Global Director of Clinical Operations. 15+ years of experience in managing clinical trials.

19 November, 2026

Researcher analyzing patient and hospital data for real-world evidence studies.

By Patricio Ledesma, Founder and CEO, Sofpromed

Table of Contents

Real-World Evidence (RWE) has become one of the most important components of modern clinical research.

Over the last fifteen years, I have seen a significant shift in how pharmaceutical companies, biotech sponsors, medical device developers, and academic investigators generate clinical evidence.

Randomized controlled trials (RCTs) remain the gold standard for demonstrating efficacy and safety, but they cannot answer every question.

Increasingly, healthcare stakeholders want to understand how treatments perform in routine clinical practice, across broader patient populations, and over longer periods of time.

That is where Real-World Evidence studies play a critical role.

At Sofpromed, we have supported sponsors worldwide in the planning, execution, monitoring, and analysis of observational studies, patient registries, retrospective chart reviews, prospective non-interventional studies, and post-authorization safety studies.

These projects often appear simpler than interventional clinical trials, but in reality they require substantial operational expertise, regulatory knowledge, robust data management, and sophisticated statistical methodologies.

In this article, I will explain how a Clinical Research Organization (CRO) supports Real-World Evidence studies from start to finish, including ethics approvals, site contracts, project management, monitoring, data management, statistical analyses, and reporting.

I will also describe how we at Sofpromed support sponsors globally in the successful execution of these studies.

Understanding Real-World Evidence Studies

The U.S. Food and Drug Administration (FDA) defines Real-World Evidence as clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of Real-World Data (RWD).

Table 1. Real-World Data Sources

Source

Examples

Electronic Health Records (EHR)

Epic, Cerner, Meditech

Disease Registries

Oncology registries, rare disease registries

Claims Databases

Insurance claims and reimbursement records

Hospital Databases

Laboratory results, imaging databases

Pharmacy Records

Drug dispensing information

Wearables and Digital Health Tools

Smartwatches, remote monitoring devices

Patient Reported Outcomes

Quality-of-life surveys

National Health Systems

Population health databases

The pharmaceutical industry increasingly relies on RWE to support:

  • Regulatory submissions
  • Health technology assessments (HTAs)
  • Market access activities
  • Post-marketing surveillance
  • Safety evaluations
  • Label expansion strategies
  • Rare disease research
  • Comparative effectiveness research

The global growth of RWE studies has created a need for CROs that can manage these projects efficiently while ensuring scientific rigor and compliance with local regulations.

Why Sponsors Use CROs for RWE Studies

One of the most common misconceptions is that non-interventional studies are easy to conduct.

In reality, many sponsors underestimate the operational complexity involved.

Consider a multinational observational oncology study involving:

  • 150 sites
  • 20 countries
  • 3,000 patients
  • 5 years of follow-up

Even though patients receive standard-of-care treatment, sponsors still need:

  • Ethics approvals
  • Site contracts
  • Data collection tools
  • Monitoring oversight
  • Quality control processes
  • Safety reporting procedures
  • Statistical analysis plans
  • Clinical study reports

Without experienced operational support, timelines can quickly become delayed.

An experienced CRO provides a structured operational framework that allows sponsors to focus on scientific objectives while the CRO manages execution.

Study Feasibility and Project Planning

Every successful RWE study starts with a comprehensive feasibility assessment.

At Sofpromed, we begin by evaluating:

Patient Availability

We determine:

  • Expected patient populations
  • Incidence and prevalence rates
  • Geographic distribution
  • Recruitment capabilities

Data Availability

Not all healthcare systems collect the same information.

We assess:

Table 2. Availability of Data in RWE Studies

Data Element

Availability Assessment

Demographics

High

Safety Data

High

Biomarkers

Variable

Imaging Data

Variable

Quality of Life Data

Often Limited

Survival Data

Generally High

This early planning prevents costly protocol amendments later.

Country Selection

Different countries have different requirements regarding:

  • Data privacy
  • Ethics approvals
  • Patient consent
  • Secondary use of healthcare data

Selecting appropriate countries early significantly improves timelines.

Ethics Committee and Regulatory Approvals

One of the most important CRO responsibilities is obtaining ethics approval.

Many sponsors assume observational studies face minimal regulatory oversight.

This is not true.

Depending on the jurisdiction, approvals may be required from:

  • Ethics Committees (ECs)
  • Institutional Review Boards (IRBs)
  • Data Protection Authorities
  • Hospital Research Offices
  • National Competent Authorities

Table 3. Ethics Approval Requirements for RWE Studies

Region

Ethics Approval Required

European Union

Yes

United Kingdom

Yes

United States

Usually IRB

Canada

Research Ethics Board

Australia

Human Research Ethics Committee

Japan

Institutional Ethics Committee

A CRO coordinates submission packages and communication with these authorities.

At Sofpromed, our regulatory specialists prepare:

  • Study protocols
  • Informed consent forms
  • Patient information sheets
  • Investigator documentation
  • Data privacy documentation
  • GDPR compliance packages

Data Privacy and GDPR Compliance

Data privacy has become one of the most critical aspects of RWE studies.

Modern observational projects frequently involve:

  • Cross-border data transfer
  • Large patient datasets
  • Secondary use of health data

Compliance is mandatory.

Table 4. Common Regulations for Data Protection

Region

Regulation

European Union

GDPR

United Kingdom

UK GDPR

United States

HIPAA

Brazil

LGPD

Canada

PIPEDA

Singapore

PDPA

Failure to comply can jeopardize an entire study.

At Sofpromed, data privacy assessments are integrated into every project from the initial planning stage.

Site Identification and Site Contracting

After approvals are obtained, sites must be activated.

This is often one of the biggest bottlenecks in study startup.

Activities include:

  • Site qualification
  • Budget negotiation
  • Contract negotiation
  • Documentation collection
  • Investigator training

Large observational studies frequently include:

  • Academic hospitals
  • Community healthcare networks
  • Private clinics
  • Disease centers of excellence

Each institution typically requires separate contractual discussions.

Common Contract Elements

  • Data ownership
  • Publication rights
  • Patient compensation
  • Data transfer obligations
  • Confidentiality requirements
  • Study termination rights

At Sofpromed, our clinical operations teams manage site contracting globally, helping sponsors avoid lengthy startup delays.

Investigator Meetings and Site Training

Once sites are activated, training becomes essential.

Although RWE studies are non-interventional, data quality depends heavily on site performance.

Training topics may include:

  • Protocol requirements
  • Data collection procedures
  • Electronic data capture systems
  • Safety reporting
  • Privacy requirements
  • Missing data prevention

We frequently conduct:

  • Investigator meetings
  • Web-based training
  • Site initiation visits
  • Refresher training sessions

These investments significantly improve data quality later.

Monitoring in Real-World Evidence Studies

Many people believe monitoring is unnecessary in observational research.

In my experience, that assumption is dangerous.

The monitoring strategy may differ from a Phase III clinical trial, but oversight remains essential.

Objectives of RWE Monitoring

Monitoring helps verify:

  • Protocol compliance
  • Data completeness
  • Data consistency
  • Source document availability
  • Safety reporting compliance

Risk-Based Monitoring

Modern RWE studies often utilize risk-based approaches.

Table 5. Risk-Based Monitoring Activities in RWE Studies

Monitoring Activity

Typical Frequency

Remote Monitoring

Monthly

Centralized Monitoring

Continuous

On-Site Monitoring

Risk-Based

Data Quality Reviews

Weekly

Query Reviews

Ongoing

This approach reduces costs while maintaining quality.

At Sofpromed, our monitoring teams combine centralized review with targeted site visits based on predefined risk indicators.

Safety Surveillance

Safety oversight remains relevant in many observational studies.

Depending on study objectives, sponsors may need:

  • Adverse event collection
  • Serious adverse event evaluation
  • Pharmacovigilance reporting
  • Periodic safety reviews

This becomes particularly important in:

  • PASS studies
  • Post-marketing commitments
  • Long-term follow-up research

Our pharmacovigilance specialists support global safety reporting requirements and maintain compliance with local regulations.

Data Management: The Foundation of Reliable RWE

Data management is often the most underestimated component of Real-World Evidence research.

Poor-quality data produces unreliable evidence.

No statistical methodology can fully compensate for poor underlying data quality.

Data Sources

Modern RWE projects may combine:

  • Electronic medical records
  • eCRF data
  • Registry information
  • Laboratory databases
  • Wearable device outputs
  • Patient-reported outcomes

Managing these diverse datasets requires specialized expertise.

eCRF Design and Database Development

At Sofpromed, our data management team designs study databases that maximize both usability and data quality.

Activities include:

Database Specification

  • Variable definition
  • Edit check planning
  • Validation rules
  • User role configuration

eCRF Development

Platforms may include:

  • Medidata Rave
  • Veeva Vault EDC
  • OpenClinica
  • REDCap
  • Castor EDC

User Acceptance Testing

Before deployment we verify:

  • Functionality
  • Data validation
  • Reporting outputs
  • Query behavior

This reduces downstream issues substantially.

Data Cleaning and Quality Management

Large RWE datasets often contain:

  • Missing values
  • Duplicate records
  • Inconsistent measurements
  • Coding discrepancies

Systematic data cleaning is therefore essential.

Typical processes include:

Table 6. Data Review Activities in RWE Studies

Data Review Activity

Purpose

Query Management

Resolve discrepancies

Range Checks

Identify impossible values

Consistency Checks

Verify logical relationships

Medical Coding

Standardize terminology

Duplicate Reviews

Remove redundant records

At Sofpromed, dedicated data managers continuously review quality indicators throughout the study lifecycle.

Statistical Analysis

Biometrics represents one of the most critical CRO functions in Real-World Evidence studies.

A common misconception is that RWE analyses are simpler than randomized trials.

In fact, they are often more statistically challenging.

Because treatment assignment is not randomized, multiple sources of bias can affect study outcomes.

Statistical Challenges in RWE

Potential biases include:

  • Selection bias
  • Confounding
  • Information bias
  • Missing data bias
  • Immortal time bias
  • Channeling bias

Addressing these issues requires advanced analytical techniques.

Statistical Analysis Planning

Every study should include a robust Statistical Analysis Plan (SAP).

A high-quality SAP defines:

  • Primary endpoints
  • Secondary endpoints
  • Analysis populations
  • Missing data methodologies
  • Sensitivity analyses
  • Subgroup analyses

At Sofpromed, our statisticians develop SAPs tailored specifically to observational study designs.

Advanced Statistical Methodologies

Common methodologies include:

Propensity Score Methods

Used to reduce treatment allocation bias.

Examples:

  • Propensity score matching
  • Stratification
  • Weighting
  • Covariate adjustment

Survival Analysis

Frequently used in oncology and rare disease studies.

Methods include:

  • Kaplan-Meier estimation
  • Cox proportional hazards models
  • Competing risks models

Longitudinal Data Analysis

Useful for long-term follow-up studies.

Examples:

  • Mixed-effect models
  • Repeated measures analyses
  • Generalized estimating equations

Causal Inference Approaches

Increasingly important for regulatory-grade RWE.

Methods may include:

  • Inverse probability weighting
  • Marginal structural models
  • Instrumental variable analyses

Statistical Programming

The complexity of modern RWE requires experienced programmers.

Our statistical programming group typically uses:

Table 7. Statistical Programming Software Types

Software

Typical Application

SAS

Regulatory analyses

R

Advanced analytics

Python

Data processing

SQL

Database extraction

Power BI

Dashboard reporting

Programs are validated according to predefined quality standards.

Study Reporting and Publications

Once data analysis is complete, results must be communicated appropriately.

Deliverables often include:

  • Study reports
  • Regulatory reports
  • Scientific manuscripts
  • Congress abstracts
  • Health economics publications

A CRO assists with the production of all these outputs.

At Sofpromed, we regularly support publication strategies for sponsors seeking to maximize the scientific value of their data.

How Sofpromed Supports Global RWE Studies

Over the years, we have built a flexible model specifically designed to support Real-World Evidence programs worldwide.

Our services include:

Regulatory Affairs

  • Ethics submissions
  • Regulatory strategy
  • GDPR support
  • Privacy assessments

Clinical Operations

  • Site identification
  • Site activation
  • Monitoring
  • Project management

Data Management

  • Database design
  • eCRF development
  • Data cleaning
  • Medical coding

Biometrics

  • Statistical analysis plans
  • Statistical programming
  • Data analysis
  • Reporting

Pharmacovigilance

  • Safety oversight
  • Case processing
  • Signal detection support

A Typical Global RWE Project at Sofpromed

A typical multinational observational study supported by Sofpromed may involve:

Table 8. Characteristics of a Typical RWE Project Managed by Sofpromed

Project Component

Typical Scope

Countries

10–30

Sites

50–300

Patients

500–10,000+

Follow-up Duration

1–10 Years

Database Records

Millions

Safety Reports

Hundreds

To manage such programs effectively, our teams coordinate activities across regulatory, clinical, data management, biometrics, and pharmacovigilance functions.

This integrated model helps sponsors maintain consistency and quality across all participating countries.

Why Sponsors Choose CRO Support for RWE Studies

From my perspective, the biggest advantage a CRO brings to an RWE study is operational expertise.

Sponsors may conduct only a handful of observational programs each year.

CROs manage dozens simultaneously and develop specialized processes that reduce risk, improve efficiency, and accelerate timelines.

The right CRO can help sponsors:

  • Launch studies faster
  • Improve data quality
  • Reduce protocol deviations
  • Maintain regulatory compliance
  • Generate publishable evidence
  • Support market access objectives
  • Prepare regulatory-grade analyses

These benefits become increasingly important as regulatory agencies and payers place greater emphasis on Real-World Evidence.

Final Remarks

Real-World Evidence studies have evolved from secondary research projects into strategic evidence-generation programs that influence regulatory decisions, reimbursement negotiations, clinical guidelines, and patient care.

Although they may appear less complex than traditional clinical trials, successful RWE studies require substantial expertise in ethics approvals, site contracting, project management, monitoring, data management, statistical analysis, and reporting.

In my experience, the greatest risk in Real-World Evidence research is not lack of data.

Today, healthcare systems generate enormous volumes of information.

The real challenge is transforming that information into credible scientific evidence.

That transformation requires the right methodology, the right operational infrastructure, and the right biometrics expertise.

At Sofpromed, we support pharmaceutical companies, biotech organizations, medical device developers, and academic investigators worldwide by providing comprehensive Real-World Evidence services, from protocol development and ethics submissions through data management, statistical analysis, and final reporting.

Our objective is simple: to help sponsors generate reliable evidence that ultimately improves patient care and supports better healthcare decisions around the world.

Patricio Ledesma

Patricio Ledesma (B.Eng Concordia University, Montreal, Canada and Master’s Degree in Clinical Trials, University of Seville, Spain) is the Head of Clinical Operations and Founder at Sofpromed CRO. Patricio is a professional consultant providing comprehensive, one-stop expert advice and guidance to biotechnology and pharmaceutical companies worldwide in the field of clinical trials and drug development. He is personally and enthusiastically devoted to helping biotech Chief Executive, Operations, Scientific, Medical, and Regulatory Officers in the planning and execution of phase I-IV clinical trials across North America, Europe, Asia-Pacific, Latin America, and Middle East regions. You can contact Patricio at: +34 607 939 266  pledesma@sofpromed.com 

You may also be interested...

Patricio Ledesma

Patricio Ledesma (B.Eng Concordia University, Montreal, Canada and Master’s Degree in Clinical Trials, University of Seville, Spain) is the Head of Clinical Operations and Founder at Sofpromed CRO. Patricio is a professional consultant providing comprehensive, one-stop expert advice and guidance to biotechnology and pharmaceutical companies worldwide in the field of clinical trials and drug development. He is personally and enthusiastically devoted to helping biotech Chief Executive, Operations, Scientific, Medical, and Regulatory Officers in the planning and execution of phase I-IV clinical trials across North America, Europe, Asia-Pacific, Latin America, and Middle East regions. You can contact Patricio at: +34 607 939 266 pledesma@sofpromed.com